D015 Aldosterone plays a pro-angiogenic role by enhancing VEGF-A production in immune cells

Background and aim VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by their capacity to secrete VEGF-A. Moreover, these cells possess mineralocorticoid receptors. The present study was designed t...

Full description

Saved in:
Bibliographic Details
Published inArchives of cardiovascular diseases Vol. 102; p. S41
Main Authors Walczak, C, Gaignier, F, Bello, G, GILET, A, Thornton, S, Lacolley, P, Ropars, A
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and aim VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by their capacity to secrete VEGF-A. Moreover, these cells possess mineralocorticoid receptors. The present study was designed to investigate whether aldosterone (Aldo) was able to regulate VEGF-A production of immune cells. Methods HL-60 (progranulocytic) and THP-1 (promonocytic) cell lines and human blood neutrophils and monocytes were incubated for different times with Aldo (10-7, 10-8, 10-9 M). Total cellular RNA extraction, submitted to reverse transcription and real time quantitative PCR was used to study VEGF-A mRNA expression. Cell supernatants were collected and ELISA tests were performed to analyse VEGF-A protein excretion. Results All four cell types increased their VEGF-A mRNA and protein production. VEGF-A mRNA expression increased from 30 mn and time for maximal expression depended on cell type: 30 mn for HL-60 and THP-1 cells, and for blood neutrophils 3 hours after Aldo addition. ELISA tests showed increased excretion of VEGF-A proteins after 24 hours of Aldo contact for all four cell types. Western-blotting performed with HL-60 and THP-1 cells showed that ERK1/2 and p38 pathways are stimulated by Aldo. ERK1/2, p38 and PI3kinase transduction signal inhibitors decreased this immune cell activation orchestrated by Aldo. Conclusion We have demonstrated that Aldo is able to increase VEGF-A production of phagocytic cells such as neutrophils and monocytes. This phenomenon is PI3K, ERK1/2 and p38 dependent. These cells play an important role in tissue healing notably by their capacity to degrade dead cells and to secrete pro-angiogenic factors such as VEGF-A in situ. It appears that Aldo could play an important role in this neovascularisation process by favouring cell proliferation and tissue building.
AbstractList Background and aim VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by their capacity to secrete VEGF-A. Moreover, these cells possess mineralocorticoid receptors. The present study was designed to investigate whether aldosterone (Aldo) was able to regulate VEGF-A production of immune cells. Methods HL-60 (progranulocytic) and THP-1 (promonocytic) cell lines and human blood neutrophils and monocytes were incubated for different times with Aldo (10-7, 10-8, 10-9 M). Total cellular RNA extraction, submitted to reverse transcription and real time quantitative PCR was used to study VEGF-A mRNA expression. Cell supernatants were collected and ELISA tests were performed to analyse VEGF-A protein excretion. Results All four cell types increased their VEGF-A mRNA and protein production. VEGF-A mRNA expression increased from 30 mn and time for maximal expression depended on cell type: 30 mn for HL-60 and THP-1 cells, and for blood neutrophils 3 hours after Aldo addition. ELISA tests showed increased excretion of VEGF-A proteins after 24 hours of Aldo contact for all four cell types. Western-blotting performed with HL-60 and THP-1 cells showed that ERK1/2 and p38 pathways are stimulated by Aldo. ERK1/2, p38 and PI3kinase transduction signal inhibitors decreased this immune cell activation orchestrated by Aldo. Conclusion We have demonstrated that Aldo is able to increase VEGF-A production of phagocytic cells such as neutrophils and monocytes. This phenomenon is PI3K, ERK1/2 and p38 dependent. These cells play an important role in tissue healing notably by their capacity to degrade dead cells and to secrete pro-angiogenic factors such as VEGF-A in situ. It appears that Aldo could play an important role in this neovascularisation process by favouring cell proliferation and tissue building.
VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by their capacity to secrete VEGF-A. Moreover, these cells possess mineralocorticoid receptors. The present study was designed to investigate whether aldosterone (Aldo) was able to regulate VEGF-A production of immune cells. HL-60 (progranulocytic) and THP-1 (promonocytic) cell lines and human blood neutrophils and monocytes were incubated for different times with Aldo (10-7, 10-8, 10-9 M). Total cellular RNA extraction, submitted to reverse transcription and real time quantitative PCR was used to study VEGF-A mRNA expression. Cell supernatants were collected and ELISA tests were performed to analyse VEGF-A protein excretion. All four cell types increased their VEGF-A mRNA and protein production. VEGF-A mRNA expression increased from 30 mn and time for maximal expression depended on cell type: 30 mn for HL-60 and THP-1 cells, and for blood neutrophils 3 hours after Aldo addition. ELISA tests showed increased excretion of VEGF-A proteins after 24 hours of Aldo contact for all four cell types. Western-blotting performed with HL-60 and THP-1 cells showed that ERK1/2 and p38 pathways are stimulated by Aldo. ERK1/2, p38 and PI3kinase transduction signal inhibitors decreased this immune cell activation orchestrated by Aldo. We have demonstrated that Aldo is able to increase VEGF-A production of phagocytic cells such as neutrophils and monocytes. This phenomenon is PI3K, ERK1/2 and p38 dependent. These cells play an important role in tissue healing notably by their capacity to degrade dead cells and to secrete pro-angiogenic factors such as VEGF-A in situ. It appears that Aldo could play an important role in this neovascularisation process by favouring cell proliferation and tissue building.
Author Thornton, S
Lacolley, P
Bello, G
Ropars, A
Gaignier, F
GILET, A
Walczak, C
Author_xml – sequence: 1
  fullname: Walczak, C
– sequence: 2
  fullname: Gaignier, F
– sequence: 3
  fullname: Bello, G
– sequence: 4
  fullname: GILET, A
– sequence: 5
  fullname: Thornton, S
– sequence: 6
  fullname: Lacolley, P
– sequence: 7
  fullname: Ropars, A
BookMark eNqFkE1LAzEQhoNU0FZ_gpCjHlbzsbvZXJRSaxUKHvy4eAjZZLZGt0lJWmH_vdtWPHgRBmYYZh7e9x2igQ8eEDqj5JISWl490UoUGaO8PCfyQjDGikweoOOfNasGvzMvj9AwpQ9CSiZEeYzebgkt8Li1Ia0h9ly8anWXsMarGDLtFy4swDuDY2gB1x0G_669cX6BX6ezu2y8vbMbs3bBY9fXcrnpIQbaNp2gw0a3CU5_-gi93E2fJ_fZ_HH2MBnPM0MLITNhqqYXDdIIlteG21rUvKhzkZO6sZblTFJLwYqqASk1hZyQphaacJCa84qPULHnmhhSitCoVXRLHTtFidompHYJqa19RaTaJaRk_3ez_4Ne3JeDqJJx4A1YF8GslQ3uX8L1H4JpXZ-Wbj-hg_QRNtH3zhVViSmyh2wZRO4Ikn8DhOqD6A
ContentType Journal Article
Copyright Elsevier Masson SAS
2009 Elsevier Masson SAS
Copyright_xml – notice: Elsevier Masson SAS
– notice: 2009 Elsevier Masson SAS
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1016/S1875-2136(09)72225-9
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1875-2128
EndPage S41
ExternalDocumentID 10_1016_S1875_2136_09_72225_9
S1875213609722259
1_s2_0_S1875213609722259
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
0SF
1B1
1P~
1~.
1~5
23M
4.4
457
4G.
53G
5GY
5VS
6I.
6J9
7-5
71M
8P~
AACTN
AAEDT
AAEDW
AAFTH
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAXKI
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABVKL
ABXDB
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADMUD
ADVLN
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AEXQZ
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BAWUL
BKOJK
BLXMC
BNPGV
CS3
DIK
EBS
EFJIC
EJD
EO9
EP2
EP3
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
IXB
J1W
KOM
LN9
M41
MO0
N9A
NCXOZ
O-L
O9-
OAUVE
OA~
OK1
OL0
OZT
P-8
P-9
PC.
Q38
RIG
ROL
SDF
SDG
SEM
SES
SPCBC
SSH
SSZ
T5K
UNMZH
Z5R
~G-
AAIAV
ABLVK
ABYKQ
AJBFU
EFLBG
LCYCR
AAYXX
CITATION
ID FETCH-LOGICAL-c1579-7c8f722e9c724bc3db7b35b4740bfdd24291d1ed78fe99a1e400fb7a03e9a3383
IEDL.DBID ABVKL
ISSN 1875-2136
IngestDate Thu Sep 26 19:52:04 EDT 2024
Fri Feb 23 02:20:48 EST 2024
Tue Oct 15 22:54:13 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1579-7c8f722e9c724bc3db7b35b4740bfdd24291d1ed78fe99a1e400fb7a03e9a3383
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S1875213609722259
ParticipantIDs crossref_primary_10_1016_S1875_2136_09_72225_9
elsevier_sciencedirect_doi_10_1016_S1875_2136_09_72225_9
elsevier_clinicalkeyesjournals_1_s2_0_S1875213609722259
PublicationCentury 2000
PublicationDate 2009
PublicationDateYYYYMMDD 2009-01-01
PublicationDate_xml – year: 2009
  text: 2009
PublicationDecade 2000
PublicationTitle Archives of cardiovascular diseases
PublicationYear 2009
Publisher Elsevier Masson SAS
Publisher_xml – name: Elsevier Masson SAS
SSID ssj0062776
Score 1.8127514
Snippet Background and aim VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and...
VEGF-A has been described to be an important pro-angiogenic factor. Immune cells are intimately involved in tissue repair and neovascularisation notably by...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage S41
SubjectTerms Cardiovascular
Internal Medicine
Title D015 Aldosterone plays a pro-angiogenic role by enhancing VEGF-A production in immune cells
URI https://www.clinicalkey.es/playcontent/1-s2.0-S1875213609722259
https://dx.doi.org/10.1016/S1875-2136(09)72225-9
Volume 102
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61WwlxQTzFQql84AAHdxPHidfH7dJlS2E5QKsVHCw7tkukKl017aEXfjszeRQQiANSpMiO7TiT8Tdje2YM8LIoi9x553mQWcIlBZ-1wlrunZJWOJFH31pbrIrliXy3ztdbMB98Ycisssf-DtNbtO5zJj01J5uqmnxKUdUWaVZQABrkSr0NO4K2mUawMzs4PX4_AHIhVHvGHJXnVOGnI0_XSJv5KtGv23a4_ruI-kXsLO7DvV5fZLOuSw9gK9QP4c6Hfkf8EXx9g5KWzc49OWtcXtSBbc7tTcMsQ2jktj6rLpBFqpKRGSFzNyzU3yjERn3GTg_fLviMyvkuhCyr8CJ_kcBoPb95DCeLw8_zJe8PTOBlmivNVTmN-A1Bl0pIV1LoZJflTiqZuOg9SmOd-jR4NY1Ba5sGHMDRKZtkQVuaqz6BUY09fQoMEx4fZq7QUfpYTEWU1uPoFcKmNotj2B9oZDZdXAxzazBGRDVEVJNo0xLV6DGogZJmcPpEmApNP2Yak5pGmMT88V_HML2t-RtrGET9f7_02f9XfQ53u40jWm3ZhdHV5XV4gfrHlduD7f3v6V7PZXQ_Ol6uMPdofYCp1Xz98csPCkDYIg
link.rule.ids 315,786,790,3525,4043,4521,24144,27600,27954,27955,27956,45618,45696,45712,45907
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV05T-wwEB7BIgEN4hTL6YICCr-NHSdelytgWa5tgCekV1h2bEMkFFYECv49dg4OPUSBlCaOr0xmvpnYM2OAvTRLE220wZbFEWYh-ayiSmGjOVNU08SZyttinI5u2NltcjsFh20sTHCrbLC_xvQKrZuSXkPN3iTPe1fEm9qUxGlIQOO5UkzDDEs4oR2YGZyej8YtIKeUV2fMhfo4NPgI5Kk7qQr3I3FQ9YPF9yrqk9oZLsJCYy-iQT2lJZiyxTLMXjY74ivw78hrWjR4MCFY4-mxsGjyoF5LpJCHRqyKu_zRs0ieoeBGiPQrssV9SLFR3KG_xydDPAj1TJ1CFuX-CvEiFoX1_HIVbobH14cj3ByYgDOScIF51nf-HazIOGU6C6mTdZxoxlmknTFeGwtiiDW876wQilgvwE5zFcVWqPCvugadws90HZC_Mf5hrFPhmHFpnzqmjJdeShVRsevCn5ZGclLnxZDvDmOBqDIQVUZCVkSVogu8paRsgz49TNmykZlSEllSGcn_vmsX-u8tv7CG9Kj_86Abv2-6C3Oj68sLeXE6Pt-E-XoTKay8bEHn-enFbntb5FnvNLz2Brb71cE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=D015+Aldosterone+plays+a+pro-angiogenic+role+by+enhancing+VEGF-A+production+in+immune+cells&rft.jtitle=Archives+of+cardiovascular+diseases&rft.au=Walczak%2C+C.&rft.au=Gaignier%2C+F.&rft.au=Bello%2C+G.&rft.au=GILET%2C+A.&rft.date=2009&rft.pub=Elsevier+Masson+SAS&rft.issn=1875-2136&rft.eissn=1875-2128&rft.volume=102&rft.spage=S41&rft.epage=S41&rft_id=info:doi/10.1016%2FS1875-2136%2809%2972225-9&rft.externalDocID=S1875213609722259
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F18752136%2FS1875213609X70269%2Fcov150h.gif